Events in November, 2018
Society of Neuroscience (SfN) 48th annual meeting
SfN’s 48th annual meeting, Neuroscience 2018, is the world’s largest neuroscience conference for scientists and physicians devoted to understanding the brain and nervous system. SfN invites you to its renowned venue where neuroscientists collaborate and network with peers, learn from experts, explore the newest neuroscience tools and technologies, and discover great career opportunities. Neuroscience 2018 is November 3-7 at the San Diego Convention Center. Join more than 30,000 colleagues from more than 80 countries at the world’s largest marketplace of ideas and tools for global neuroscience.
Location: San Diego, CA
Nov. 4-7, 2018
American Association Pharmaceutical Scientists PharmSci360 Annual Meeting
AAPS PharmSci 360 will combine all the energy of a large scientific conference with the intimacy of a small niche gathering. There are five robust tracks covering all aspects of the pharmaceutical sciences. Each track will be split equally between chemical and biomolecule areas, resulting in 10 sub-tracks that will cover many of the areas making the biggest headlines in the pharmaceutical sciences today.
Location: Washington DC, USA
More information: https://www.aaps.org/aaps/pharmsci/annual-meeting
Nov. 5-8, 2018
Society for Glycobiology (SFG) Annual Meeting
The Society for Glycobiology is a nonprofit scholarly society devoted to the pursuit of knowledge of glycan structures and functions, and to the sharing of that knowledge among scientists worldwide.
Location: New Orleans, LA, USA
More information: http://glycobiology.org/
Nov. 6, 2018
Scholarship and discount abstract deadline: Keystone Symposia - Diabetes: Innovations, Outcomes and Personalized Therapies (X3) joint with the meeting on Unraveling the Secrets of Kidney Disease (X4)
Location: Whistler, British Columbia, Canada
More information: http://keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=1631
Nov. 7-9, 2018
Southeastern Regional Lipid Conference
The Southeastern Regional Lipid Conference (SERLC) is one of the largest and most established academic meetings on lipid biology research in the United States. The main themes are sphingolipids, phospholipids, and eicosanoids, their analysis by state of the art lipidomics, and their biological functions in cell signaling, cell biology and in physiological and pathophysiological processes, including metabolic and infectious diseases, immunology and cancer.
Location: Cashiers, NC, USA
More information: https://serlc.us/
Nov. 7, 2018
ENDO2019 Abstract Submission Deadline
ENDO 2019 is coming to the Ernest N. Morial Convention Center in New Orleans, LA, from March 23-26, 2019. It promises to be an experience you can’t miss with an extensive program featuring cutting-edge science, poster sessions, Meet-the-Professor sessions, the newest products and technologies at ENDOExpo, and more.
Location: New Orleans, LA, USA
More information: https://www.endocrine.org/endo2019
Nov. 11-15, 2018
Obesity Week 2018
ObesityWeek is a unique, international event focused on the basic science, clinical application, surgical intervention and prevention of obesity. By combining both American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS) annual meetings, ObesityWeek brings together world-renowned experts in obesity to share innovation and breakthroughs in science unmatched around the globe. Attendees will enjoy the diverse educational opportunities, networking events, and scientific synergies created through the collaboration of these leading obesity organizations.
Location: Nashville, TN, USA
More information: https://tosconnect.obesity.org/events/event-description?CalendarEventKey=15d181a4-0c66-445f-80a4-7a144219c7ec&Home=/meetings/events-calendar
Nov. 11-15, 2018
TOS NORC Symposium
An inaugural TOS NORC Symposium will take place during Obesity Week 2018 in Nashville, Tennessee (November 11-15, 2018). The Chair for this event will be Dr. Jerrold Heindel, formerly of NIEHS, who will give an overview of the topic. This symposium will be supported by an administrative supplement, which was submitted by the Boston NORC.
Location: Nashville, TN, USA
More information: https://norccentral.org/2018/05/tos-norc/
Nov. 11-14, 2018
Imaging Mass Spectrometry Society (IMSS II) & OURCON Conference
This conference plans to highlight the many advances in the field of Mass Spectrometry Imaging, promote research of students and new investigators, and acknowledge the top scientists who have helped to cultivate this innovative atmosphere over the years. This conference plans to offer a plethora of accelerating networking opportunities through demos, lectures and additional group activities.
Location: Charleston, SC, USA
More information: https://www.imagingmssociety.org/IMSS_II-OurCon_VI
Nov. 11-13, 2018
The fourth Lipidomics Forum
This symposium is an annual series of conferences on lipid biology and lipidomics to provide a platform for international acknowledged scientists, students, and young researchers to interact. Specifically, we will encourage students to participate by poster presentations and short talks allowing them to receive advice from experts in the field. Therefore, this symposium series will not only cover current research highlights but also offer tutorials on selected methodical topics. We are convinced to have created a stimulating and scientifically attractive fourth edition of the Lipidomics Forum especially for you.
More information: https://lipidomics-forum.isas.de/
Nov. 12-13, 2018
TOS pre-conference workshop: MOUSE MODELS OF OBESITY
Experimental mouse models of obesity have shed light into the mechanisms of weight gain and mechanisms to prevent it. The ability to manipulate the genome has led to the identification of neural and systemic causes of obesity. Moreover, targets for pharmaceutical agents have been identified in the mouse. Despite the number of existing genetic mouse models of obesity and the ability to create new ones, the ability to study the physiology of the mouse remains challenging. This is due to the small size of the mouse. This workshop will describe physiological, environmental, and surgical tools to study mouse models of obesity using state-of-the-art tools.
More information: https://obesityweek.com/session/vanderbilt-mouse-metabolic-phenotyping-center-presents-approaches-to-studying-mouse-models-of-obesity/
Nov. 12, 2018
NIDDK Meeting Registration Deadline: Collaborating for the Advancement of Interdisciplinary Research in Benign Urology
The purpose of the Collaborating for the Advancement of Interdisciplinary Research in Benign Urology meeting is to bring together the Directors of the O?Brien Urology Centers and their project directors, the Directors of the Planning Centers for Interdisciplinary Research in Benign Urology, and the Directors for the Multidisciplinary K12 Urologic Research (KURe) Career Development Program and their fellows. This meeting will promote interactions between Centers and Programs and the sharing of resources.
More information: https://www.niddk.nih.gov/news/meetings-workshops/2018/urology-program-directors-meeting-2018
Nov. 14, 2018
Abstract Submission Deadline: Experimental Biology 2019 Annual Meeting
Experimental Biology (EB) is the largest and most prestigious interdisciplinary meeting of its kind. Life sciences and biomedical researchers from all over the world meet to network and share cutting-edge research that leads to discoveries and career advancement. EB welcomes everyone with interest in anatomy, biochemistry and molecular biology, investigative pathology, pharmacology, and physiology.
More information: http://experimentalbiology.org/2019/home.aspx
Nov. 14, 2018
Abstract Submission Deadline: The ISSCR International Symposia - Stem Cells & Organoids in Development & Disease
Stem Cells & Organoids in Development & Disease offers three days of insightful presentations and conversations around a research topic at the forefront of our field. Renowned keynote speakers Hans Clevers and Jürgen Knoblich will give the opening and closing talks; in between, hear from invited experts from around the globe, and abstract-selected speakers presenting their latest research.
Nov. 15-30, 2018
3rd International Electronic Conference on Metabolomics
Building on the success of IECM-1 in 2016 and IECM-2 in 2017, Metabolites (ISSN 2218-1989), a peer-reviewed, scientific journal, edited by MDPI, is proud to be the organizer and sponsor of the third International Electronic Conference on Metabolomics. Contributions dealing with any discipline promoting metabolism and metabolomics will be welcomed.
More information: https://sciforum.net/conference/iecm-3
Nov. 28-30, 2018
The 4th Australian Lipids Meeting
The 4th Australian Lipids Meeting aims to bring together lipid researchers from different fields to discuss their work, current technology, and facilitate cross-disciplinary collaboration.
More information: https://www.centenary.org.au/research/alm4/
Nov. 28-30, 2018
World Vaccine & Immunotherapy Conference
After an incredibly successful inaugural year, the World Vaccine and Immunotherapy Congress is back in 2018 to bring you more content, learning and business development opportunities so you can take advantage of the rich biotech and funding environment that the West Coast offers.Whilst still focussing on the vaccine and immunotherapy industry the scope of the event has expanded considerably and will delve deeper into topics surrounding vaccine development, cancer immunotherapy, funding and partnerships as well as exploring new topics in clinical trials & development, bioprocessing, manufacture and delivery, and the development and use of antibodies for both infectious diseases and cancer.
More information: https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/index.stm
Funding opportunities information and deadlines in November, 2018
Nov. 1, 2018
NIDDK Funding Opportunity Application Due Date: Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK. The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This targeted FOA specifically seeks to generate scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease.
More information: https://grants.nih.gov/grants/guide/pa-files/PA-18-891.html
Nov. 1, 2018
NIDDK Funding Opportunity Application Due Date: New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional)
NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK. The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This targeted FOA specifically seeks to generate scientific advancements that are focused on identifying new signals and regulatory networks that mediate metabolic cross talks within and between organs that play a role in the development of diabetes and obesity. The interdisciplinary approaches proposed should be designed to foster novel synergies that will accelerate conceptual and technical breakthroughs in science related to metabolic tissue communication.
More information: https://grants.nih.gov/grants/guide/pa-files/PAR-18-886.html
Nov. 1, 2018
NIDDK Funding Opportunity Application Due Date: Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R34 Clinical Trial Required)The purpose of this Funding Opportunity Announcement (FOA) is to seek research applications that pilot test approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care. Research applications should be developed to pilot test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal is that, if the pilot study shows promising results, the data from the R34 will be used to support a full-scale trial focused on improving routine healthcare practice and informing healthcare policy for the prevention or management of diabetes and obesity. Therefore, interventions must be integrated into the existing healthcare structure and/or processes. The healthcare setting may not be used solely as a venue for recruitment.
More information: https://grants.nih.gov/grants/guide/pa-files/PAR-18-924.html
Nov. 6, 2018
NIDDK Funding Opportunity Letter of Intent Due Date: Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for Type 1 Diabetes (T1D). The purpose is to accelerate the discovery of function of the causal genes and variants that influence the risk for disease.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-005.html
Nov. 6, 2018
NIDDK Funding Opportunity Letter of Intent Due Date: Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.
Nov. 11, 2018
NIDDK Funding Opportunity Letter of Intent Due Date: Human Islet Research Network - Consortium on Human Islet Biomimetics (HIRN-CHIB) (UG3/UH3 Clinical Trial Not Allowed)
This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-011.html
Nov. 12, 2018
NIDDK Funding Opportunity Application Due Date: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
The overarching goal of this Funding Opportunity Announcement (FOA) is to translate basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematology, and specific aspects of cystic fibrosis. Additional information concerning programmatic areas at NIDDK is available at: www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx. Its objective is to stimulate research and technology development to promote the early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics (e.g. antibodies, cell-based therapies, engineered tissue constructs, probiotic or commensal microbes) that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in either the target, small molecule, or non-viral biologic itself, or in the approaches used to pursue further therapeutic lead validation, and that this is articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, or generating lists of putative new targets. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity of modulating a target’s activity for safe, efficacious treatment of a disease using a small molecule or non-viral biologic approach.
Nov. 13, 2018
Funding Opportunity Application Deadline: The Chan Zuckerberg Initiative Seed Networks for the Human Cell Atlas
The Human Cell Atlas (HCA) is a global effort to create a reference map of all cell types in the human body. It is an ambitious goal to generate a fundamental reference for biomedical research. The Chan Zuckerberg Initiative and the Helmsley Charitable Trust are pleased to announce continued support for the Human Cell Atlas by collaborating on two new funding mechanisms that the community can access through a single application portal. The Chan Zuckerberg Initiative seeks to continue the work of the HCA community with a focus on interdisciplinary work and collaboration through the formation of 3 year Seed Networks. The Helmsley Charitable Trust welcomes ?applications? ?that will construct a detailed atlas of the human gut. CZI Seed Networks aim to solidify growth of the community and result in a first draft of several organs - there is no requirement for a gut component in CZI applications. Additionally, newly formed Networks are designed to catalyze partnership among the scientific community and the funding community so that we can work together toward a first draft of the HCA.
Nov. 14, 2018
JDRF Funding Opportunity Application Due Date: Innovative Strategies To Demonstrate “Immunological Proof-of-Mechanism” And To Explore Early Outcome Measures In Immunotherapy Trials
Investigators/groups will address any or all of the following:
1) Define a measure or measures that will allow evaluation of candidate immune therapies for treatment effect, in a shorter timescale and with fewer subjects than current practice.
2) Explore early outcome measures that are surrogates for clinical efficacy in immunotherapy trials.
3) Define a lower burden outcome measure that may be frequently sampled with easier tools and technologies than currently available.
4) Define a measure/score for therapeutic effect, incorporating measures that represent early alterations in disease course after interventions.
5) Other novel approaches to determine early readouts of immune therapeutic effect and/or link such to improved, earlier outcomes in T1D immunotherapy trials.